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abstRact
IntroductIon: Polymyalgia rheumatica (PMR) is an in-
flammatory disorder that affects the elderly. At present,  
evidence is limited regarding the usefulness of positron 
emission tomography-computed tomography (PET-CT) in 
the diagnosis of PMR. This study aimed to compare patient 
characteristics and symptoms with PET-CT findings in a  
Danish population of PMR patients without clinical symp-
toms of giant cell arteritis.
Methods: The medical records of 50 Danish PET-CT-scan- 
ned patients with PMR were reviewed. Symptoms, charac-
teristics and PET-CT findings were registered from the med-
ical records. 
results: Fluorodeoxyglucose (FDG) uptake was seen at the 
shoulders and/or hips of about 80%, and at the spinous pro-
cesses of about 50% of the patients. Furthermore, 14% of 
the patients showed no FDG uptake at any of the studied 
locations. A sensitivity of 79% for PMR was found if there 
was FDG uptake at any two of the following three locations: 
the shoulder, the hip and the spinous processes. Vascular 
FDG uptake was seen in 7% of the patients. No significant 
correlations between any symptoms and any PET-CT find-
ings were found. C-reactive protein was significantly lower 
in patients receiving glucocorticoids, and completely normal 
scans were seen significantly more often in patients receiv-
ing steroid treatment.
conclusIons: PET-CT is a sensitive imaging technique in 
PMR patients. Symptoms and PET-CT findings do not corre-
late in PMR. Steroid treatment prior to PET-CT reduces the 
scan’s ability to demonstrate inflammation in PMR patients. 
FundIng: none.
trIal regIstratIon: not relevant.
Polymyalgia rheumatica (PMR) is a chronic inflammatory 
disorder characterised by pain and stiffness of the neck, 
shoulders, upper arms, hips and thighs [1]. The cause of 
the disorder currently remains unknown, but it is well 
known that it is most common in people of Northern  
European descent, and predominantly in elderly women 
[1]. PMR occurs as a separate entity, but is also present 
in 40-60% of patients with giant cell arteritis (GCA). Con-
versely, 16-21% of PMR patients have GCA, and it re-
mains unclear whether the two disorders are different 
manifestations of the same disease or represent separ-
ate entities [1]. The diagnosis is usually based upon 
medical history, clinical examination and biochemical 
evidence of inflammation [1]. In an effort to improve di-
agnostic accuracy, several sets of diagnostic criteria have 
been proposed by various authors [1]. Ultrasonography 
(US) has been shown in several studies to be beneficial 
in distinguishing PMR from other conditions with similar 
symptomatology, reflected by the presence of US crit-
eria in the classification criteria proposed by the Europ-
ean League Against Rheumatism and the American Col-
lege of Rheumatology [2, 3]. The usefulness of novel 
imaging techniques, such as 18F-labelled fluorodeoxyglu-
cose (FDG) positron emission tomography/computed 
tom ography (PET-CT), is well documented in the diagno-
sis and monitoring of therapy for cancer and has also 
been used in the diagnosis of certain inflammatory dis-
eases [4]. However, evidence is limited regarding PET-CT 
findings in PMR patients. This study aimed to retrospect-
ively compare patient characteristics and symptoms 
with corresponding PET-CT findings in a Danish popula-
tion of PMR patients without clinical signs of GCA.
mEthOds
Patients were recruited from a register of patients diag-
nosed with PMR, GCA with PMR, or GCA without PMR at 
the Department of Rheumatology, Odense University 
Hospital, Denmark, in the 2014-2015 period. Permission 
to access the patients’ medical records for the purposes 
of this study was granted by the Danish Health Author-
ity. Patients were included if their medical record re-
vealed that: 1) they had a diagnosis of PMR established 
by a rheumatologist and 2) a PET-CT had been made at 
Odense University Hospital, after March 2010. The ex-
clusion criteria were: 1) The PET-CT had not been made 
as a part of the process of investigation (e.g. physical ex-
ams, blood sample analyses, imaging) that led to the pa-
tient receiving a PMR diagnosis. 2) Presence of cranial 
isch aemic symptoms (e.g. headache, visual symptoms) 
or a positive temporal artery biopsy, indicating GCA.  
A total of 50 patients were included after performing 
the above steps in 210 patients. The decision to include 
50 patients was made solely for pragmatic reasons. The 
medical records of the 50 patients were reviewed, and 
information regarding patient characteristics, constitu-
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tional symptoms (i.e. fever, weight loss, night sweats, 
malaise) and musculoskeletal system symptoms (e.g. 
pain, morning stiffness) was registered. The nuclear 
medicine physician’s description of the PET-CT was scru-
tinised, and if more than one PET-CT scan had been 
made, the findings in the one closest to the date of the 
patient’s PMR diagnosis were used. The descriptions 
were made by various nuclear medicine physicians over 
a course of 3.5 years, and were based on a visual exam-
ination of the PET-CT. We registered FDG uptake at the 
shoulder, the hip, the spinous processes at any level, the 
ischial tuberosity, the vasculature and the sternoclavicu-
lar joint. Additionally, presence of pathological FDG up-
take at any other location was registered. 
Statistical analysis was made using Excel 2013, with 
the RealStats and Solver add-ins. For analysis of continu-
ous variables, the Kruskal-Wallis test was used as these 
variables could not be assumed to be normally distribut-
ed. For comparison of binary variables, Fisher’s exact 
test was used. Medians are presented with the range in 
parentheses.
Trial registration: not relevant.
REsUlts
The median age of the patients was 74 (range: 46-88) 
years, 62% were female. The patients had a median 
 diagnostic delay of 27 (range: 0-333) days (table 1).  
The median CRP before treatment was elevated to 57 
(range: 2-246) mg/l. Almost all patients had upper ex-
tremity pain (98%), most had lower extremity pain (88%) 
and many had neck/back pain (70%). The diagnostic crit-
eria for PMR, proposed by Healey [5], were met in 46% 
of the patients (table 2). PET-CTs were performed due 
to suspicion of malignant disease in slightly more than 
half of the patients. FDG uptake was found primarily in 
the shoulders, hips, spinal column, ischial tuberosities 
and in the sternoclavicular joints (table 3). A temporal 
artery biopsy was made in nine (31%) cases, one was in-
conclusive, the rest were negative. A total of 21 patients 
were receiving glucocorticoid treatment at the time of 
their PET-CT, and seven (33%) of these patients had nor-
mal PET-CTs. In contrast, no steroid-naïve patients had 
completely normal PET-CTs (p = 0.001). CRP at the time 
of the PET-CT was significantly lower in patients receiv-
ing glucocorticoid treatment than in steroid-naïve pa-
tients; the median CRP was 7 (range: 0-57) mg/l versus 
40 (range: 2-255) mg/l, p < 0.0001. Because of these 
findings, indicating that glucocorticoid treatment might 
introduce bias, the remainder of the statistical analyses 
were made on the glucocorticoid-naïve patients exclu-
sively. 
No significant correlations were found between any 
localised pain and FDG uptake in the corresponding re-
gion of interest (ROI). Furthermore, presence of consti-
tutional symptoms did not correlate with vascular FDG 
uptake (table 4). No significant correlations between 
CRP values and FDG uptake could be found at any ROI. 
Sensitivity of the FDG-positive PET-CT for the diagnosis 
of PMR was calculated when combining the following 
three ROIs: shoulder, hip and spinous processes. A sensi-
tivity of 48% was achieved if there was FDG uptake at all 
three locations simultaneously. Furthermore, if there 
was FDG uptake at any two of these three locations, a 
sensitivity of 76% was achieved. Conversely, only 14% of 
patients had a finding of only “other pathological up-
take” or no uptake at all. As this study did not include a 
control group, no specificities could be calculated.
tablE 1
Patient characteristics. 
all patients  
(n = 50)
steroid naive  
patients (n = 29)
Female sex, n (%) 31 (62) 18 (62)
Age at diagnosis, yrs, median (range) 74 (46-88) 76 (46-88)
Time from 1st consultation to diagnosis, days, median (range) 27 (0-333) 21 (0-333)
Time from PET-CT to diagnosis, days, median (range) 9 (–83-322) 10 (–13-322)
CRP before treatment with glucocorticoids, mg/l
Mean (± SD) 67 (± 55.0) 64 (± 62.8)
Median (range) 57 (2-246) 49 (2-246)
On glucocorticoid treatment at the time of PET/CT, n (%) 21 (42) 0
Clinical suspicion triggering PET-CT, n (%)
Cancer 31 (62) 18 (62)
Infection   7 (14)   7 (24)
Vasculitis/PMR 11 (22)   4 (14)
Other   1 (2)   0
CRP = C-reactive protein; PET-CT = positron emission tomography-computed tomography; PMR = poly-
myalgia rheumatica; SD = standard deviation.
tablE 2
Symptoms or clinical manifestations related to polymyalgia rheumatica in patients. The values are n (%).
all patients  
(n = 50)
steroid naïve  
patients (n = 29)
yes INP/II yes INP/II
Upper extremity pain 49 (98)   1 (2) 29 (100)   0
Lower extremity pain 44 (88)   3 (6) 25 (86)   1 (3)
Back and/or neck pain 35 (70) 12 (24) 22 (76)    6 (21)
Morning stiffness 12 (24) 38 (76)   7 (24) 22 (76)
Constitutional symptoms 32 (64) 17 (34) 22 (76)   7 (24)
Rapid response to glucocorticoids 29 (58) 10 (20) 15 (52)   9 (31)
Clinical evidence of arthritis   9 (18)   6 (12)   3 (10)   3 (10)
US evidence of bursitis   2 (4) 45 (90)   1 (3) 26 (90)
Ischaemic symptoms   0 45 (90)    0 27 (93)
Healey criteria fulfilled [5] 23 (46) 22 (44) 14 (48) 12 (41)
INP/II = information not provided/insufficient information; US = ultrasonographic.
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discUssiOn
In the Danish PMR patients included in this study, in-
creased FDG uptake in the shoulders and hips was very 
common, whereas FDG uptake at the spinous processes 
was less frequent. Increased FDG uptake at the sterno-
clavicular joint and the ischial tuberosity was occasional-
ly seen, whereas vascular FDG uptake was rare. Surpris-
ingly, other pathological uptake than what is typically 
found in PMR was found in roughly three out of five pa-
tients. Most of these findings were non-specific, but in a 
few cases the PET-CT findings warranted further investi-
gation (e.g. colonoscopy and biopsy). 
The patients were given their PMR diagnosis by a 
rheumatologist, but only half of the patients fulfilled the 
criteria proposed by Healey [5]. This was primarily be-
cause the data required to fulfil these criteria were miss-
ing in the patients’ medical records. This probably re-
flects the records being every-day clinical tools and not 
data gathered for scientific purposes, a well-known 
problem in the retrospective study design. It is not 
known to which degree the results of the PET-CT influ-
enced the rheumatologist when the PMR diagnosis was 
given, as it was not specified in the medical records. 
A clear majority of the 29 steroid-naïve patients had 
a very low time delay (days to a few weeks) from PET-CT 
to a PMR diagnosis was established. Only four patients 
had a considerable time delay exceeding two months. 
This patient number is too low to have skewed the re-
sults.
The very high frequencies of FDG uptake at the 
shoulders and at the hips in this study are similar to the 
frequencies reported by Yamashita et al [4], Blockmans 
et al [6], Rehak et al [7], Palard-Novello et al [8] and 
Wakura et al [9], confirming a high prevalence of this 
finding in PMR patients. However, a history of upper or 
lower extremity pain does not seem to correlate with 
these findings. In the present study, there were several 
patients without upper and/or lower extremity pain who 
had an increased FDG uptake at these locations. To our 
knowledge this has not yet been investigated elsewhere. 
The findings are in contrast to the rather low frequency 
of FDG uptake at these sites reported by Sondag et al 
[10] (58% had FDG uptake at the shoulders, 38% at the 
hips), but 44% of the PMR patients in that study were 
treated with corticosteroids, which may lower FDG up-
take. The findings of the present study also confirm the 
findings by Camellino et al [11] that FDG uptake at the 
spinous processes is fairly common (48% of patients), 
but no connection to columnar pain could be made. 
Hence, increased FDG uptake detectable by PET-CT 
might not demonstrate the inflammatory changes re-
sponsible for the reported regional pain symptoms. 
Similarly, an imaging study including 57 PMR patients  
revealed that US evidence of subacromial bursitis re-
mained in nearly 60% of patients, even after clinical  
remission or low disease activity was achieved [12].
Our finding of a sensitivity of 76% when combining 
the PET-CT findings at the hips, shoulders and spinous 
processes is not surprising as a high frequency of FDG 
uptake at these locations in PMR patients has also been 
found in other studies [4, 6-8, 13, 14]. However, some 
authors have reported that FDG uptake at the hips and 
shoulders is unsuitable for distinguishing between PMR 
and similar diseases (e.g. rheumatoid arthritis), as the 
specificity is low [13], unless the pattern of FDG uptake 
at these locations is considered [14]. 
The finding of a significant negative effect of gluco-
corticoid treatment on PET-CT findings is similar to find-
ings reported by Blockmans et al. The authors were able 
to demonstrate a significant reduction in FDG uptake at 
the shoulders, hips and spinous processes after three 
months of methylprednisolone therapy [6]. Similarly,  
in a study of GCA patients, previously abnormal PETs 
were normalised in eight out of 22 patients after three 
months of methylprednisolone treatment [15]. Sondag 
et al also found that FDG uptake was significantly lower 
in PMR patients receiving steroid treatment [10]. 
A potential connection between CRP values and 
PET-CT findings could not be demonstrated in this study. 
Similarly, Stellingwerff et al were unable to establish a 
tablE 3
Positron emission tomography-computed tomography findings. The values are n (%).
all patients  
(n = 50)
steroid naïve  
patients (n = 29)
Fdg uptake yes nd yes nd
Shoulder 33 (66)   5 (10) 23 (79)   4 (14)
Spinous process 18 (36) 13 (26) 14 (48) 10 (34)
Hip 34 (68)   4 (8) 24 (83)   3 (10)
Vascular   4 (8) 23 (46)   2 (7) 19 (66)
Ischial tuberosity 13 (26) 19 (38)   9 (31) 15 (52)
Sternoclavicular joint 13 (26) 17 (34) 10 (34) 12 (41)
Other pathological 25 (50) 10 (20) 17 (59)   8 (28)
FDG = 18F-labelled fluorodeoxyglucose; ND = not described.
tablE 4
FDG uptake by patient-reported symptoms in the 29 steroid naïve patients.
FDG uptake, n/N (%)
symptom: location of Fdg uptake yes no p-value
Any columnar pain: spinous processes (n = 22) 11/14 (76) 11/15 (73) NS
Lower extremity pain: hip (n = 25) 21/24 (88) 4/5 (80) NS
Lower extremity pain: ischial tuberosity (n = 25) 8/9 (89) 17/20 (85) NS
Constitutional symptoms: vascular (n = 22) 2/2 (100) 20/27 (74) NS
FDG = 18F-labelled fluorodeoxyglucose; NS = not significant (p ≥ 0.05).
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statistically significant difference in CRP values between 
positive and negative FDG PETs in their study of GCA pa-
tients [16]. In contrast, Moosig et al reported a positive 
correlation between quantitative PET measures and CRP 
values in PMR patients (r = 0.8, p < 0.001) [17]. Similarly, 
Einspieler et al reported a positive correlation between 
CRP values and the number of vascular segments af-
fected by vasculitis both when evaluated by PET/MRI  
(r = 0.92, p < 0.0001) and by PET alone (r = 0.75, p = 
0.0067) in large vessel vasculitis patients. However,  
regarding disease activity, no significant correlation  
between quantitative PET results and CRP was found  
(r = 0.55, p = 0.0651) by the authors [18].
There is a notable discrepancy between the re-
ported frequencies of vascular FDG uptake in the various 
studies made of PET-CT findings in PMR patients. This 
might, at least in part, be due to the different methods 
used by authors to assess whether abnormal FDG up-
take was present. Using the FDG uptake of the liver as a 
reference point when assessing a ROI for possible ab-
normal uptake has been shown to be the most reliable 
method when assessing vascular FDG uptake [19]. Some 
of the discrepancy may also be due to inclusion of pa-
tients with possible GCA in some studies of PMR pa-
tients and therefore possibly a higher frequency of vas-
cular FDG uptake [15, 20].
The lack of statistically significant differences de-
tected in this study may be due to the small sizes of the 
analysed groups. A strength of this study is the every-
day nature of the patient cohort, which is readily com-
parable to the average Danish PMR patient in a second-
ary referral centre. Furthermore, inclusion of 50 patients 
is a relatively large number in this context.
cOnclUsiOns
A majority of PMR patients have an increased uptake at 
specific locations. Neither regional nor constitutional 
symptoms correlate with PET-CT findings in PMR. This 
study supports previous evidence that steroid treatment 
prior to FDG PET-CT reduces the ability of the scan to 
demonstrate inflammation in PMR patients. Large pro-
spective studies of PET-CT findings in PMR patients with 
inclusion of relevant control groups are warranted as 
PET-CT at present remains an expensive, not readily 
available imaging modality.
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